UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Blood, 2016-06, Vol.127 (25), p.3237-3252

2016

Volltextzugriff (PDF)

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

British journal of haematology, 2017-06, Vol.177 (5), p.808-813

2017

Volltextzugriff (PDF)

Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma

BME frontiers, 2021-01, Vol.2021, p.9860123-9860123

2021

Volltextzugriff (PDF)

Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

Blood, 2018-04, Vol.131 (15), p.1720-1729

2018

Volltextzugriff (PDF)

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Journal of clinical oncology, 2018-09, Vol.36 (27), p.2755-2761

2018

Volltextzugriff (PDF)

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies

Journal of clinical oncology, 2020-04, Vol.38 (11), p.1198-1208

2020

Volltextzugriff (PDF)

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Blood, 2017-05, Vol.129 (18), p.2519-2525

2017

Volltextzugriff (PDF)

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

Blood advances, 2020-01, Vol.4 (1), p.141-153

2020

Volltextzugriff (PDF)

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

British journal of haematology, 2019-11, Vol.187 (3), p.356-363

2019

Volltextzugriff (PDF)

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

Blood, 2018-05, Vol.131 (18), p.2047-2059

2018

Volltextzugriff (PDF)

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

Blood, 2016-08, Vol.128 (6), p.827-838

2016

Volltextzugriff (PDF)

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance

Blood, 2021-11, Vol.138 (20), p.1966-1979

2021

Volltextzugriff (PDF)

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

British journal of haematology, 2019-01, Vol.184 (2), p.242-245

2019

Volltextzugriff (PDF)

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Blood advances, 2019-10, Vol.3 (19), p.2800-2803

2019

Volltextzugriff (PDF)

Analyzing Spatial Transcriptomics Data Using Giotto

Current protocols, 2022-04, Vol.2 (4), p.e405-n/a

2022

Volltextzugriff (PDF)

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

Blood cancer journal (New York), 2020-01, Vol.10 (1), p.12-12, Article 12

2020

Volltextzugriff (PDF)

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia

Blood advances, 2020-09, Vol.4 (18), p.4550-4553

2020

Volltextzugriff (PDF)

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Blood, 2019-11, Vol.134 (Supplement_1), p.3778-3778

2019

Volltextzugriff (PDF)

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Blood, 2019-11, Vol.134 (Supplement_1), p.2823-2823

2019

Volltextzugriff (PDF)

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Blood, 2018-11, Vol.132 (Supplement 1), p.1563-1563

2018

Volltextzugriff (PDF)

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1372-1372

2018

Volltextzugriff (PDF)

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

Blood, 2018-11, Vol.132 (Supplement 1), p.1566-1566

2018

Volltextzugriff (PDF)

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Blood, 2019-11, Vol.134 (Supplement_1), p.394-394

2019

Volltextzugriff (PDF)

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Blood, 2016-12, Vol.128 (22), p.2931-2931

2016

Volltextzugriff (PDF)

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

Blood, 2016-12, Vol.128 (22), p.2764-2764

2016

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(45)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia

Multimodal Metabolic Imaging Reveals Pigment Reduction and Lipid Accumulation in Metastatic Melanoma

Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia

Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas

CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib

BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance

TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia

CXCR4 S338X clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

Analyzing Spatial Transcriptomics Data Using Giotto

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

Comparative genomics of CXCR4MUT and CXCR4WT single cells in Waldenström's macroglobulinemia

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTKC481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

Suchergebnisse filtern